1. Home
  2. SWTX vs BC Comparison

SWTX vs BC Comparison

Compare SWTX & BC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SWTX
  • BC
  • Stock Information
  • Founded
  • SWTX 2017
  • BC 1845
  • Country
  • SWTX United States
  • BC United States
  • Employees
  • SWTX N/A
  • BC N/A
  • Industry
  • SWTX Biotechnology: Pharmaceutical Preparations
  • BC Homebuilding
  • Sector
  • SWTX Health Care
  • BC Consumer Discretionary
  • Exchange
  • SWTX Nasdaq
  • BC Nasdaq
  • Market Cap
  • SWTX 3.5B
  • BC 3.2B
  • IPO Year
  • SWTX 2019
  • BC N/A
  • Fundamental
  • Price
  • SWTX $46.26
  • BC $47.95
  • Analyst Decision
  • SWTX Buy
  • BC Buy
  • Analyst Count
  • SWTX 7
  • BC 13
  • Target Price
  • SWTX $56.86
  • BC $72.54
  • AVG Volume (30 Days)
  • SWTX 8.7M
  • BC 1.1M
  • Earning Date
  • SWTX 05-20-2025
  • BC 04-24-2025
  • Dividend Yield
  • SWTX N/A
  • BC 3.57%
  • EPS Growth
  • SWTX N/A
  • BC N/A
  • EPS
  • SWTX N/A
  • BC 1.22
  • Revenue
  • SWTX $191,589,000.00
  • BC $5,093,900,000.00
  • Revenue This Year
  • SWTX $86.36
  • BC $3.87
  • Revenue Next Year
  • SWTX $69.02
  • BC $5.46
  • P/E Ratio
  • SWTX N/A
  • BC $39.45
  • Revenue Growth
  • SWTX 3417.33
  • BC N/A
  • 52 Week Low
  • SWTX $28.21
  • BC $41.00
  • 52 Week High
  • SWTX $62.00
  • BC $87.65
  • Technical
  • Relative Strength Index (RSI)
  • SWTX 58.93
  • BC 50.41
  • Support Level
  • SWTX $46.10
  • BC $45.44
  • Resistance Level
  • SWTX $46.27
  • BC $47.81
  • Average True Range (ATR)
  • SWTX 0.90
  • BC 1.64
  • MACD
  • SWTX 0.58
  • BC 0.69
  • Stochastic Oscillator
  • SWTX 99.46
  • BC 88.89

About SWTX SpringWorks Therapeutics Inc.

SpringWorks Therapeutics Inc is a clinical-stage biopharmaceutical company applying a precision medicine approach to acquiring, developing, and commercializing life-changing medicines for underserved patient populations suffering from devastating rare diseases and cancer. The company has a differentiated portfolio of small molecule targeted oncology product candidates and is advancing two potentially registrational clinical trials in rare tumor types, as well as several other programs addressing prevalent, genetically defined cancers. OGSIVEO, the first commercial product, is a novel, oral, selective gamma-secretase inhibitor. GOMEKLI, the second commercial product, is an oral, small molecule mitogen-activated protein kinase, or MEK, inhibitor.

About BC Brunswick Corporation

Brunswick is a leading manufacturer in the marine recreation industry. The firm has more than 60 brands delivering products across propulsion (outboard, sterndrive, and inboard engines, propulsion-related controls, rigging, and propellers), parts, accessories, and technology, and boats (including well-known brands like Boston Whaler and Sea Ray). It also owns numerous Freedom Boat Club locations as well as Boateka, which facilitates transactions in the used-boat market. Brunswick's focus surrounds building the innovative marine and recreational experiences, technologies, and connections supported by quality and innovation.

Share on Social Networks: